Secukinumab: First IL-17A Antagonist for Plaque Psoriasis

Pharmacy Today
doi 10.1016/s1042-0991(15)30449-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psoriasis: IL-17A-Antikörper Garantieren Raschen Wirkeintritt

hautnah dermatologie
2017English

Dyshidrotic Eczema in Two Patients on Secukinumab for Plaque Psoriasis: A Case Report

SAGE Open Medical Case Reports
2020English

The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond

Expert Review of Clinical Immunology
AllergyImmunology
2019English

IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A

Journal of Immunology
AllergyImmunology
2010English

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

Frontiers in Immunology
AllergyImmunology
2020English

Psoriasis and the MAITing Game: A Role for IL-17A+ Invariant TCR CD8+ T Cells in Psoriasis?

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2014English

Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab

Cornea
Ophthalmology
2015English

Drug Survival of Secukinumab in Real-World Plaque Psoriasis Patients: A 52-Week, Multicenter, Retrospective Study

Journal of the American Academy of Dermatology
Dermatology
2018English

Transcriptome Profiling Unveils the Role of Cholesterol in IL-17A Signaling in Psoriasis

Scientific Reports
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy